Octapharma Sweden in the news
Manufacturing life-saving drugs
Tamtam found 20 recent articles about Octapharma Sweden.
- Meet Octapharma, the Swiss Biopharma Giant Planning a $1.5 Billion Rock Hill Campus
Octapharma, a Swiss biopharmaceutical company, is investing $1.5 billion to build its first U.S. manufacturing facility and relocate its U.S. headquarters to Rock Hill, South Carolina, creating over 1,200 jobs.
- Entering a New Era in Protection in Haemophilia A
The 2025 EAHAD symposium in Milan focused on new approaches to protecting Haemophilia A patients, featuring leading experts with ties to major pharma including Octapharma.
- FDA Clears Freeze-Dried Plasma Transfusion Powder for Military Emergency Use
Octapharma USA received FDA clearance for a freeze-dried plasma powder designed for emergency military transfusions in remote combat zones.
- Octapharma USA Receives FDA Emergency Use Authorization for octaplasLG Powder, Allows U.S. Military Medical Providers Emergent Use in Treatment of Hemorrhage or Coagulopathy
Octapharma USA gained FDA emergency authorization for its freeze-dried plasma powder to treat bleeding in U.S. military emergencies when fresh plasma is unavailable.
- Octapharma USA Appoints Kelly Hearn as Vice President of Commercial Marketing & Development
Kelly Hearn joins Octapharma USA as VP of Commercial Development & Marketing to lead product marketing and support U.S. growth in blood disorder therapies.
- Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®, the First VWF Concentrate for Prophylaxis in All Types of VWD
FDA grants orphan drug exclusivity to Octapharma's wilate®, the first approved VWF concentrate for prophylactic treatment in all types of von Willebrand disease.
- Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®, the First VWF Concentrate for Prophylaxis in All Types of VWD
The FDA has granted orphan drug exclusivity to wilate as the first prophylactic treatment for all types of von Willebrand disease.
- Octapharma Data Breach Investigation
Octapharma experienced a cybersecurity incident in April 2024 affecting its systems and potentially compromising sensitive personal data, with investigations ongoing.
- Läkemedelsjätte med fabriken mitt i city
Octapharma runs a major plasma-based drug manufacturing plant in central Stockholm, sourcing plasma mainly from the USA, producing critical protein therapies, and planning significant growth and investment.
- Läkemedelsjätte med fabriken mitt i city
Octapharma, a global leader in protein-based pharmaceuticals, operates a 24/7 manufacturing facility in Stockholm, producing life-saving drugs from blood plasma and planning significant investments for growth.
- Octapharma Announces Availability of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures
Octapharma USA launched Balfaxar , a new FDA-approved drug for urgent reversal of warfarin's anticoagulant effects in patients requiring immediate surgery or invasive procedures.
- Heroes in the Fight: Octapharma To Be Honored for Myositis Research at TMA Annual Patient Conference
Octapharma is being honored by The Myositis Association for its clinical research and for developing the first FDA-approved treatment for adult dermatomyositis.
- Octapharma USA research at AAAAI: cutaquig® study at higher infusion rates presented
Research confirms cutaquig® can be administered at higher rates and volumes to reduce infusion time and site count for primary immunodeficiency patients.
- Octapharma USA Requests FDA Approval for wilate® VWD Prophylaxis Supplement
Octapharma USA has applied for FDA approval to expand the use of wilate for routine bleeding prophylaxis in von Willebrand disease patients.
- Octapharma USA requests FDA approval for wilate® VWD prophylaxis supplement
Octapharma USA submitted an sBLA to the FDA to expand wilate's approval for routine prophylaxis in children and adults with von Willebrand disease, based on positive WIL-31 study results.
- FDA Approves Octapharma’s Octagam 10% for Adult Dermatomyositis
FDA approved Octapharma's Octagam 10% as the first intravenous immunoglobulin for treating adult dermatomyositis, based on positive results from the ProDERM study.
- FDA Approves Octapharma’s Octagam® 10% for Adult Dermatomyositis
FDA approved Octagam 10% for treating adult dermatomyositis based on a successful global clinical trial demonstrating its safety and efficacy.
- FDA Approves Octapharma’s Octagam® 10% for Adult Dermatomyositis
FDA approved Octagam 10% for treating adult dermatomyositis based on a pivotal clinical trial demonstrating its safety and efficacy.
- FDA approves Octapharma's Octagam® 10% for adult dermatomyositis
Octapharma's Octagam 10% received FDA approval for adult dermatomyositis, a rare immune-mediated inflammatory disease, based on positive results from the ProDERM clinical trial.
- Octapharma tillåter inte hemarbete
Octapharma maintains a strict no-remote-work policy for all 940 employees in Stockholm, including office staff, citing patient safety concerns related to their life-saving drug manufacturing.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Octapharma Sweden?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies